Intervention Protocol

You have free access to this content

Somatostatin analogues for treatment of enterocutaneous fistula

  1. Philip Stevens1,*,
  2. Sorrel Burden2,
  3. Raymond Delicata3,
  4. Gordon Carlson4,
  5. Simon Lal5

Editorial Group: Cochrane IBD Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010489

How to Cite

Stevens P, Burden S, Delicata R, Carlson G, Lal S. Somatostatin analogues for treatment of enterocutaneous fistula (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010489. DOI: 10.1002/14651858.CD010489.

Author Information

  1. 1

    Salford Royal NHS Foundation Trust, Surgery, Salford, UK

  2. 2

    University of Manchester, School of Nursing, Midwifery and Social Work, Manchester, UK

  3. 3

    Gwent Healthcare NHS Healthboard ? Nevill Hall Hospital, General Surgery, Abergavenny, UK

  4. 4

    Salford Royal NHS Foundation Trust, General Surgery, Salford, UK

  5. 5

    Salford Royal Foundation Trust, Intestinal Failure Unit, Salford, UK

*Philip Stevens, Surgery, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013



Additional references

Adkins 2004
Alghamdi 2007
  • Alghamdi AA, Jawas AM, Hart RS. Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. Canadian Journal of Surgery 2007;50:459-66.
Alivizatos 2002
  • Alivizatos V, Felekis D, Zorbalas A. Evaluation of the effectiveness of octreotide in the conservative treatment of postoperative enterocutaneous fistulas. Hepatogastroenterology 2002;49:1010-2.
Alvarez 2000
Atkins 2004
Bauer 1982
  • Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences 1982;31:1133-40.
Beglinger 1999
Berry 1994
  • Berry SM, Fischer JE. Enterocutaneous fistulas. Current Problems in Surgery 1994;31(6):469-566.
Berry 1996
Boike 1992
Borison 1992
Bornschein 2009
  • Bornschein J, Drozdov I, Malfertheiner P. Octreotide LAR. Safety and tolerability issues. Expert Opinion on Drug Safety Issues 2009;8:755-68.
Buchler 2002
  • Buchler MW. Gastrointestinal fistulae. Gut 2002;49(Suppl IV):iv1.
Campos 1999
  • Campos AC, Andrade DF, Campos GM, Matias JE, Coelho JC. Multivariate model to determine prognostic factors in gastrointestinal fistulas. Journal of the American College of Surgeons 1999;188:483-90.
Carlson 2003
Carlson 2010
Castañón-González 1992
  • Castañón-González JA, Miranda Ruíz R, Arías E, Fuentes Pintado E, Zárate Treviño A. The somatostatin analog SMA (201-995) as adjuvant treatment in patients with external fistulae of the digestive system. Gaceta Médica de México 1992;138(3):285-8.
Connolly 2008
  • Connolly PT, Teubner A, Lees NP, Anderson ID, Scott NA, Carlson GL. Outcome of reconstructive surgery for intestinal fistula in the open abdomen. Annals of Surgery 2008;247(3):440-4.
Coughlin 2012
  • Coughlin S, Roth L, Lurati G, Faulharber M. Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis. World Journal of Surgery 2012;36(5):1016-29.
Datta 2010
  • Datta V, Engledow A, Chan S, Forbes A, Cohen CR, Windsor A. The management of enterocutaneous fistula in a regional unit in the United kingdom: a prospective study. Diseases of the Colon and Rectum 2010;53(2):192-9.
di Costanzo 1987
  • di Costanzo J, Cano N, Martin J, Richieri JP, Mercier R, Lafille C, et al. Treatment of external gastrointestinal fistulas by a combination of total parenteral nutrition and somatostatin. Journal of Parenteral and Enteral Nutrition 1987;11:465-70.
Dubose 2010
  • Dubose JJ, Lundy JB. Enterocutaneous fistulas in the setting of trauma and critical illness. Clinics in Colon and Rectal Surgery 2010;23(3):182-9.
Edmunds 1960
Egger 1997
  • Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by simple graphical test. BMJ 1997;316(7109):629-34.
Fagniez 1999
Falconi 2001
Friess 1994
  • Friess H, Bordihn K, Ebert M, Malfertheiner P, Kemmer T, Dennler HJ, et al. Inhibition of pancreatic secretion under long-term octreotide treatment in humans. Digestion 1994;55(Suppl 1):10-5.
Gayral 2009
  • Gayral F, Campion JP, Regimbeau JM, Blumberg J, Maisonobe P, Topart P, et al. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. Annals of Surgery 2009;250:872-7.
Gerardo 1994
  • Gerardo PD, Bernardo AM. Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201–995). G.E.N. 1994;48:209-18.
Gonzalez-Pinto 2002
  • Gonzalez-Pinto I, Gonzalez EM. Optimising the treatment of upper gastrointestinal fistulae. Gut 2002;49(Suppl IV):iv21-8.
Gorden 1989
  • Gorden P, Comi RJ, Maton PN, Go VL. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumours of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Annals of Internal Medicine 1989;110:35-50.
Gouillat 2002
  • Gouillat C, Gigot JF. Pancreatic surgical complications, the case for prophylaxis. Gut 2002;49(Suppl IV):iv32-9.
Guyatt 2008
  • Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
Haffejee 2004
Hernandez-Aranda 1996
  • Hernandez-Aranda JC, Gallo-Chico B, Flores-Ramirez LA, Avalos-Huante R, Mago-Vazquez FJ, Ramirez-Barba EJ. Treatment of enterocutaneous fistula with or without octreotide and parenteral nutrition. Nutrición Hospitalaria 1996;11:226-9.
Heron 1993
  • Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1993;76:721-7.
Hesse 2002
  • Hesse U, Ysebaert D, de Hemptinne B. Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. Gut 2002;49(Suppl IV):iv11-20.
Higgins 2003
Higgins 2011
  • Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from
Isenmann 1994
  • Isenmann R, Schielke DJ, Morl FK, Wunsch N, Vestweber KH, Doertenbach JH, et al. Adjuvant therapy with somatostatin iv in postoperative fistulae of the pancreas, gall bladder and small intestine. A multicentre randomised study. Aktuelle Chirurgie 1994;29:96-9.
Jamil 2004
  • Jamil M, Ahmed U, Sobia H. Role of somatostatin analogues in the management of enterocutaneous fistulae. Journal of the College of Physicians and Surgeons of Pakistan 2004;14:237-40.
Jenkins 1995
  • Jenkins SA, Nott DM, Baxter JN. Fluctuations in the secretion of pancreatic enzymes between consecutive doses of octreotide: implications for the management of fistulae. European Journal of Gastroenterology and Hepatology 1995;7:255-8.
Johnson 1994
  • Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. European Journal of Endocinology 1994;130:229-34.
Jost 1984
Kohler 1986
  • Kohler E, Beglinger C, Dettwiler S, Whitehouse I, Gyr K. Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas 1986;1:154-9.
Koti 2010
Kutz 1986
Kuvshinoff 1993
  • Kuvshinoff BW, Brodish RJ, McFadden DW, Fischer JE. Serum transferrin as a prognostic indicator of spontaneous closure and mortality in gastrointestinal cutaneous fistulas. Annals of Surgery 1993;217:615-23.
LaBerge 1992
  • LaBerge JM, Kerlan RK Jr, Gordon RL, Ring EJ. Nonoperative treatment of enteric fistulas: results in 53 patients. JVIR: Journal of vascular and Interventional Radiology 1992;3(2):353-7.
Lamberts 1990
  • Lamberts SW, Hofland LJ, van Koetsveld PM, Reubi JC, Bruining HA, Bakker WH, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumours:consequences with regard to diagnosis, localization, and therapy. Journal of Clinical Endocrinology and Metabolism 1990;71:566-74.
Lavy 2003
Leandros 2004
  • Leandros E, Antonakis PT, Albanopoulos K, Dervenis C, Konstadoulakis MM. Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas. Canadian Journal of Gastroenterology 2004;18:303-6.
Lesche 2009
  • Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. Journal of Clinical Endocinology and Metabolism 2009;94:654-61.
Li-Ling 2001
Lindsetmo 1994
  • Lindsetmo RO, Revhaug A. Treatment of hypersecretory ileostomy, gastrostomy and fistula of the small intestine with the somatostatin analog octreotide. Tidsskrift for den Norske Laegeforening 94;114(24):2829-30.
Lloyd 2006
Londong, 1989
  • Londong W, Angerer M, Kutz K, Landgraf R, Londong V. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989;96:713-22.
Martineau 1996
Martinez 1998
  • Martinez D, Zibari G, Aultman D, McMillan R, Mancini MC, Rush BM, et al. The outcome of intestinal fistulae: the Louisiana State University Medical Center--Shreveport experience. The American Surgeon 1998;64(3):252-4.
Martinez 2008
  • Martinez JL, Luque-de-Leon E, Mier J, Blanco-Benavides R, Robledo F. Systematic management of postoperative enterocutaneous fistulas: factors related to outcomes. World Journal of Surgery 2008;32(3):436-43.
Martinez 2012
  • Martinez JL, Luque-de-León E, Ballinas-Oseguera G, Mendez JD, Juárez-Oropeza MA, Román-Ramos R. Factors predictive of recurrence and mortality after surgical repair of enterocutaneous fistula. Journal of Gastrointestal Surgery 2012;16(1):156-63.
Mastboom 1989
Mawdsely 2008
Miller 1993
Mulvihill 1986
Niv 1991
  • Niv Y, Hadari A, Asaf V, Oren M. Closure of postoperative anastomotic fistulas with a somatostatin analogue. Harefuah 1991;120(11):647-8.
Nubiola 1989
  • Nubiola P, Badia JM, Martinez-Rodenas F, Gil MJ, Segura M, Sancho J, et al. Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995. Annals of Surgery 1989;210(1):56-8.
Nubiola-Calonge 1987
  • Nubiola-Calonge P, Badia JM, Sancho J, Gil MJ, Segura M, Sitges-Serra A. Blind evaluation of the effect of Octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output. Lancet 1987;2:672-4.
Paran 1991
  • Paran H, Neufeld D, Epstein T, Bendahan J, Freund U. Use of somatostatin analogue for intestinal and pancreatic fistulas. Harefuah 1991;120(4):185-6.
Paran 1995
Patel 1999
Pederzoli 1986
  • Pederzoli P, Bassi C, Falconi M. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin. Surgery, Gynecoloogy and Obstetrics 1986;163:428-32.
Pérez 1994
  • Pérez GD, Acosta BM. Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201–995). G.E.N. 1994;48:209-18.
Rahbour 2012
  • Rahbour G, Siddiqui MR, Ullah MR, Gabe SM, Warusavitarne J, Vaizey CJ. A meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas. Annals of Surgery 2012;256(6):946-54.
Raptis 1978
Sancho 1995
Schwartz 1989
  • Schwartz RW, Barker DE, Griffen WOJ, Ross CB, Strodel WE. Gastrointestinal disconnection and the treatment of intra-abdominal sepsis. American Surgeon 1989;55:50-4.
Schünemann 2011
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from
Scott 1993
  • Scott NA, Finnegan S, Irving MH. Octreotide and postoperative enterocutaneous fistulae: a controlled prospective study. Acta Gastro-enteroligca Belgica 1993;56:266-70.
Sheppard 1979
  • Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. Journal of Clinical Endocrinology and Metabolism 1979;48:50-3.
Sitges-Serra 1982
Sitges-Serra 1993
Sleth 1994
  • Sleth JC, Andraos Y, Borie F, Dumay R, Legroux P. Value of octreotide in the treatment of postoperative enterocutaneous fistula. Annales Françaises d’Anesthèsie et de Rèanimation 1994;12(5):738-40.
Soeters 1979
Spiliotis 1990
  • Spiliotis J, Vagenas K, Panagopoulos K, Kalfarentzos F. Treatment of enterocutaneous fistulas with TPN and somatostatin, compared with patients who received TPN only. British Journal of Clinical Practice 1990;44:616-8.
Stevens 2011
  • Stevens P, Foulkes R, Hartford-Beynon J, Delicata RJ. Systematic review and meta-analysis of the role of somatostatin analogues in the treatment of non-pancreatic enterocutaneous fistulae. European Journal of Gastroenterology and Hepatology 2011;23(10):912-22.
Torres 1992
Tulassay 1998
Van Der Krabben 2000
Wells 2013
  • Wells GA Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (accessed 20 March 2013)..
Xeropotamos 2005
  • Xeropotamos N, Nastos D, Nousias KH, Christodoulou D, Tsianos EV, Kappas AM. Octreotide plus total parenteral nutrition in patients with external digestive tract fistulas – an evaluation of our experience. Annals of Gastroenterology 2005;18:427-33.
Yuan 2011
  • Yuan Y, Ren J, Gu G, Chen J, Li J. Early enteral nutrition improves outcomes of open abdomen in gastrointestinal fistula patients complicated with severe sepsis. Nutrition in Clinical Practice 2011;26(6):688-94.